Important Safety Communication Regarding Multiple Sclerosis Drug Gilenya
The Food and Drug Administration (FDA) has issued an important safety communication regarding the multiple sclerosis drug Gilenya. Recent studies indicate that the drug may cause serious cardiovascular side effects to patients. Specifically, the drug has been linked to incidents of dangerously low heart rates and blood pressure. At least one fatality has been connected to the drug.
Gilenya is used to treat and minimize flare-up episodes of multiple sclerosis and also to delay its progression. The drug was approved by the FDA in the fall of 2010. Since that time, it has been approved for use in Canada and throughout Europe.
Popularity: 1% [?]